keyword
MENU ▼
Read by QxMD icon Read
search

cost effectiveness of pre exposure prophylaxis

keyword
https://www.readbyqxmd.com/read/28695388/measuring-acceptability-and-preferences-for-implementation-of-pre-exposure-prophylaxis-prep-using-conjoint-analysis-an-application-to-primary-hiv-prevention-among-high-risk-drug-users
#1
Roman Shrestha, Pramila Karki, Frederick L Altice, Oleksandr Dubov, Liana Fraenkel, Tania Huedo-Medina, Michael Copenhaver
Although people who use drugs (PWUD) are one of the key risk populations who could benefit from the use of pre-exposure prophylaxis (PrEP), to date, little attention has been given to incorporating PrEP into HIV prevention approaches targeting this underserved group. This study investigated the acceptability of PrEP based on a number of known PrEP attributes among high-risk PWUD in a drug treatment setting. A total of 400 HIV-negative PWUD, who reported drug- and/or sex-related risk behaviors were recruited from a methadone clinic to complete a stated preference (full-profile conjoint) survey...
July 10, 2017: AIDS and Behavior
https://www.readbyqxmd.com/read/28691439/awareness-and-willingness-to-use-hiv-pre-exposure-prophylaxis-among-men-who-have-sex-with-men-in-low-and-middle-income-countries-a-systematic-review-and-meta-analysis
#2
Siyan Yi, Sovannary Tuot, Grace W Mwai, Chanrith Ngin, Kolab Chhim, Khoundyla Pal, Ewemade Igbinedion, Paula Holland, Sok Chamreun Choub, Gitau Mburu
INTRODUCTION: To facilitate provision of pre-exposure prophylaxis (PrEP) in low- and middle-income countries (LMIC), a better understanding of potential demand and user preferences is required. This review assessed awareness and willingness to use oral PrEP among men who have sex with men (MSM) in LMIC. METHODS: Electronic literature search of Cochrane library, Embase, PubMed, PsychINFO, CINHAL, Web of Science, and Google Scholar was conducted between July and September 2016...
June 26, 2017: Journal of the International AIDS Society
https://www.readbyqxmd.com/read/28631044/-personalized-treatment-of-viral-hepatitis-of-the-present-and-the-future-hepatitis%C3%A2-b-c-delta-and-e
#3
REVIEW
R Bartenschlager, M Cornberg, T Pietschmann
Precision medicine is also possible for infectious diseases as shown for the treatment of chronic viral hepatitis, especially if different options are available. In hepatitis B virus (HBV) infection, treatment indication as well as the choice of treatment and the decisions to stop treatment are based on viral markers and alanine aminotransferase (ALT) level. Future therapies for HBV infection aiming for functional cure or even virus elimination may be even more personalized and have to take into account the immune status of a given patient...
June 19, 2017: Der Internist
https://www.readbyqxmd.com/read/28570572/optimal-costs-of-hiv-pre-exposure-prophylaxis-for-men-who-have-sex-with-men
#4
Jennie McKenney, Anders Chen, Karen W Hoover, Jane Kelly, David Dowdy, Parastu Sharifi, Patrick S Sullivan, Eli S Rosenberg
INTRODUCTION: Men who have sex with men (MSM) are disproportionately affected by HIV due to their increased risk of infection. Oral pre-exposure prophylaxis (PrEP) is a highly effictive HIV-prevention strategy for MSM. Despite evidence of its effectiveness, PrEP uptake in the United States has been slow, in part due to its cost. As jurisdictions and health organizations begin to think about PrEP scale-up, the high cost to society needs to be understood. METHODS: We modified a previously-described decision-analysis model to estimate the cost per quality-adjusted life-year (QALY) gained, over a 1-year duration of PrEP intervention and lifetime time horizon...
2017: PloS One
https://www.readbyqxmd.com/read/28542184/estimation-of-the-cost-effectiveness-of-hiv-prevention-portfolios-for-people-who-inject-drugs-in-the-united-states-a-model-based-analysis
#5
Cora L Bernard, Douglas K Owens, Jeremy D Goldhaber-Fiebert, Margaret L Brandeau
BACKGROUND: The risks of HIV transmission associated with the opioid epidemic make cost-effective programs for people who inject drugs (PWID) a public health priority. Some of these programs have benefits beyond prevention of HIV-a critical consideration given that injection drug use is increasing across most United States demographic groups. To identify high-value HIV prevention program portfolios for US PWID, we consider combinations of four interventions with demonstrated efficacy: opioid agonist therapy (OAT), needle and syringe programs (NSPs), HIV testing and treatment (Test & Treat), and oral HIV pre-exposure prophylaxis (PrEP)...
May 2017: PLoS Medicine
https://www.readbyqxmd.com/read/28538691/the-potential-cost-effectiveness-of-pre-exposure-prophylaxis-combined-with-hiv-vaccines-in-the-united-states
#6
Blythe J S Adamson, Josh J Carlson, James G Kublin, Louis P Garrison
This economic evaluation aims to support policy-making on the combined use of pre-exposure prophylaxis (PrEP) with HIV vaccines in development by evaluating the potential cost-effectiveness of implementation that would support the design of clinical trials for the assessment of combined product safety and efficacy. The target study population is a cohort of men who have sex with men (MSM) in the United States. Policy strategies considered include standard HIV prevention, daily oral PrEP, HIV vaccine, and their combination...
May 24, 2017: Vaccines
https://www.readbyqxmd.com/read/28362073/feasibility-and-acceptability-of-hiv-self-testing-among-pre-exposure-prophylaxis-users-in-kenya
#7
Kenneth Ngure, Renee Heffron, Nelly Mugo, Kerry A Thomson, Elizabeth Irungu, Njambi Njuguna, Lawrence Mwaniki, Connie Celum, Jared M Baeten
INTRODUCTION: HIV testing is key to the delivery of pre-exposure prophylaxis (PrEP): testing HIV-uninfected at-risk persons is the first step for PrEP initiation and ongoing HIV testing is an essential part of PrEP delivery. Thus, novel and cost-effective HIV-testing approaches to streamline delivery of PrEP are urgently needed. Within a demonstration project of PrEP for HIV prevention among high-risk HIV serodiscordant couples in Kenya (the Partners Demonstration Project), we conducted a pilot evaluation of HIV self-testing...
February 8, 2017: Journal of the International AIDS Society
https://www.readbyqxmd.com/read/28356043/pre-exposure-prophylaxis-for-hiv-evidence-and-perspectives
#8
Georgios K Nikolopoulos, Eirini Christaki, Dimitrios Paraskevis, Stefanos Bonovas
HIV remains an important public health issue worldwide. However, new prevention approaches have recently been developed and are very promising. Antiretroviral treatment as prevention, or as a prophylaxis after exposure to HIV, has been shown to reduce the likelihood of HIV acquisition. Over the last years, animal studies and randomized clinical trials in humans showed that antiretrovirals can also be efficacious and safe if used once daily, or intermittently, as prophylaxis before an individual is exposed to HIV (Pre-exposure Prophylaxis - PrEP)...
March 29, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/28250534/pre-exposure-rabies-prophylaxis-a-systematic-review
#9
REVIEW
Jocelyn A Kessels, Sergio Recuenco, Ana Maria Navarro-Vela, Raffy Deray, Marco Vigilato, Hildegund Ertl, David Durrheim, Helen Rees, Louis H Nel, Bernadette Abela-Ridder, Deborah Briggs
OBJECTIVE: To review the safety and immunogenicity of pre-exposure rabies prophylaxis (including accelerated schedules, co-administration with other vaccines and booster doses), its cost-effectiveness and recommendations for use, particularly in high-risk settings. METHODS: We searched the PubMed, Centre for Agriculture and Biosciences International, Cochrane Library and Web of Science databases for papers on pre-exposure rabies prophylaxis published between 2007 and 29 January 2016...
March 1, 2017: Bulletin of the World Health Organization
https://www.readbyqxmd.com/read/28222118/social-structural-behavioral-and-clinical-factors-influencing-retention-in-pre-exposure-prophylaxis-prep-care-in-mississippi
#10
Trisha Arnold, Lauren Brinkley-Rubinstein, Philip A Chan, Amaya Perez-Brumer, Estefany S Bologna, Laura Beauchamps, Kendra Johnson, Leandro Mena, Amy Nunn
Pre-exposure prophylaxis (PrEP) is a biomedical intervention that can reduce rates of HIV transmission when taken once daily by HIV-negative individuals. Little is understood about PrEP uptake and retention in care among the populations most heavily impacted by the HIV epidemic, particularly among young men who have sex with men (YMSM) in the Deep South. Therefore, this study explored the structural, social, behavioral, and clinical factors that affect PrEP use and retention in care among YMSM in Jackson, Mississippi...
2017: PloS One
https://www.readbyqxmd.com/read/28209492/reproductive-considerations-in-the-setting-of%C3%A2-chronic-viral-illness
#11
REVIEW
Brent M Hanson, Jessie A Dorais
Special considerations must be taken when patients with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C desire to become pregnant. Patients with chronic viral illnesses desire to have children at rates similar to the general population, and options are available to decrease both vertical transmission and viral transmission between partners. Preconception counseling or consultation with fertility specialists is imperative in patients with HIV, hepatitis B, and hepatitis C so that reproductive goals can be addressed and optimized...
February 14, 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28031062/maximizing-the-benefits-of-art-and-prep-in-resource-limited-settings
#12
G Akudibillah, A Pandey, J Medlock
Antiretroviral therapy (ART) is increasingly being used as an HIV-prevention tool, administered to uninfected people with ongoing HIV exposure as pre-exposure prophylaxis (PrEP) and to infected people to reduce their infectiousness. We used a modelling approach to determine the optimal population-level combination of ART and PrEP allocations required in South Africa to maximize programme effectiveness for four outcome measures: new infections, infection-years, death and cost. We considered two different strategies for allocating treatment, one that selectively allocates drugs to sex workers and one that does not...
April 2017: Epidemiology and Infection
https://www.readbyqxmd.com/read/27989271/beyond-the-90-90-90-refocusing-hiv-prevention-as-part-of-the-global-hiv-response
#13
Rachel Baggaley, Shona Dalal, Cheryl Johnson, Virginia Macdonald, Ioannis Mameletzis, Michelle Rodolph, Carmen Figueroa, Julia Samuelson, Annette Verster, Meg Doherty, Gottfried Hirnschall
INTRODUCTION: The remarkable expansion in availability of antiretroviral therapy (ART) over the past two decades has transformed HIV infection into a manageable chronic condition. People with HIV infection now live long and healthy lives on treatment that is simpler, safer and cheaper. According to UNAIDS estimates, the global coverage of ART reached 46% in 2015, resulting in a 26% decrease in annual HIV-related deaths since 2010. Such success has positioned treatment access at the centre of the global HIV response as a way to prevent mortality, morbidity and HIV transmission through a "Treat All" approach...
2016: Journal of the International AIDS Society
https://www.readbyqxmd.com/read/27970805/systematic-review-of-studies-estimating-the-cost-effectiveness-of-hiv-pre-exposure-prophylaxis-prep-in-men-who-have-sex-with-men-msm
#14
O Damm, S Scholz, W Greiner
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27900502/values-and-preferences-on-the-use-of-oral-pre-exposure-prophylaxis-prep-for-hiv-prevention-among-multiple-populations-a-systematic-review-of-the-literature
#15
Florence M Koechlin, Virginia A Fonner, Sarah L Dalglish, Kevin R O'Reilly, Rachel Baggaley, Robert M Grant, Michelle Rodolph, Ioannis Hodges-Mameletzis, Caitlin E Kennedy
Daily oral pre-exposure prophylaxis (PrEP) is the use of antiretroviral drugs by HIV-negative people to prevent HIV infection. WHO released new guidelines in 2015 recommending PrEP for all populations at substantial risk of HIV infection. To prepare these guidelines, we conducted a systematic review of values and preferences among populations that might benefit from PrEP, women, heterosexual men, young women and adolescent girls, female sex workers, serodiscordant couples, transgender people and people who inject drugs, and among healthcare providers who may prescribe PrEP...
May 2017: AIDS and Behavior
https://www.readbyqxmd.com/read/27885972/protecting-the-confidentiality-and-security-of-personal-health-information-in-low-and-middle-income-countries-in-the-era-of-sdgs-and-big-data
#16
Eduard J Beck, Wayne Gill, Paul R De Lay
BACKGROUND: As increasing amounts of personal information are being collected through a plethora of electronic modalities by statutory and non-statutory organizations, ensuring the confidentiality and security of such information has become a major issue globally. While the use of many of these media can be beneficial to individuals or populations, they can also be open to abuse by individuals or statutory and non-statutory organizations. Recent examples include collection of personal information by national security systems and the development of national programs like the Chinese Social Credit System...
2016: Global Health Action
https://www.readbyqxmd.com/read/27781100/how-can-we-achieve-universal-access-to-low-cost-treatment-for-hiv
#17
EDITORIAL
Andrew M Hill, Anton L Pozniak
Mass production of low-cost antiretrovirals (ARVs) has already allowed over 17 million individuals to access treatment for HIV infection, mainly in low-income countries. It is possible to manufacture combination ARVs for $110 per person-year, using tenofovir (TDF), lamivudine (3TC) and efavirenz (EFV). New combinations of ARVs costing as little as $60 per person-year will be available in the near future. Pre-exposure prophylaxis using TDF in combination with either 3TC or emtricitabine (FTC) could also be provided for less than $90 per person-year...
October 5, 2016: Journal of Virus Eradication
https://www.readbyqxmd.com/read/27760688/prep-implementation-in-the-asia-pacific-region-opportunities-implementation-and-barriers
#18
Iryna Zablotska, Andrew E Grulich, Nittaya Phanuphak, Tarandeep Anand, Surang Janyam, Midnight Poonkasetwattana, Rachel Baggaley, Frits van Griensven, Ying-Ru Lo
INTRODUCTION: HIV epidemics in the Asia-Pacific region are concentrated among men who have sex with men (MSM) and other key populations. Pre-exposure prophylaxis (PrEP) is an effective HIV prevention intervention and could be a potential game changer in the region. We discuss the progress towards PrEP implementation in the Asia-Pacific region, including opportunities and barriers. DISCUSSION: Awareness about PrEP in the Asia-Pacific is still low and so are its levels of use...
2016: Journal of the International AIDS Society
https://www.readbyqxmd.com/read/27760687/towards-a-fair-consideration-of-prep-as-part-of-combination-hiv-prevention-in-latin-america
#19
Giovanni Ravasi, Beatriz Grinsztejn, Ricardo Baruch, Juan Vicente Guanira, Ricardo Luque, Carlos F Cáceres, Massimo Ghidinelli
INTRODUCTION: Despite progress in scaling up antiretroviral treatment, HIV prevention strategies have not been successful in significantly curbing HIV incidence in Latin America. HIV prevention interventions need to be expanded to target the most affected key populations with a combination approach, including new high impact technologies. Oral pre-exposure prophylaxis (PrEP) is recommended as additional prevention choice for individuals at higher risk of infection and could become a cost-effective prevention tool...
2016: Journal of the International AIDS Society
https://www.readbyqxmd.com/read/27760685/implementation-of-pre-exposure-prophylaxis-for-human-immunodeficiency-virus-infection-progress-and-emerging-issues-in-research-and-policy
#20
Carlos F Cáceres, Annick Borquez, Jeffrey D Klausner, Rachel Baggaley, Chris Beyrer
BACKGROUND: In this article, we present recent evidence from studies focused on the implementation, effectiveness and cost-effectiveness of pre-exposure prophylaxis (PrEP) for HIV infection; discuss PrEP scale-up to date, including the observed levels of access and policy development; and elaborate on key emerging policy and research issues to consider for further scale-up, with a special focus on lower-middle income countries. DISCUSSION: The 2015 WHO Early Release Guidelines for HIV Treatment and Prevention reflect both scientific evidence and new policy perspectives...
2016: Journal of the International AIDS Society
keyword
keyword
114595
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"